A Study of Nivolumab and Relatlimab in People With Glioblastoma

Full Title

A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma, Immunotherapy, Advancement with Nivolumab and Relatlimab (GIANT)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Thomas Kaley’s office at 212-639-5122.

Protocol
26-056
Phase
Phase II (phase 2)
Investigator
Thomas J. Kaley
Co-Investigators
Tejus A. Bale
Christian Grommes
Diseases
Brain Tumors, Primary
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06816927
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description